Finanzen von Drugs Made In America Acquisition Corp (DMAA)DMAADrugs Made In America Acquisition Corp

Evaluating the bottom line, Drugs Made In America Acquisition Corp. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of 3.33%, provide a clear picture of how effectively DMAA converts its operational activities into shareholder value.

In the context of the broader market, DMAA competes directly with industry leaders such as OACC and CATL. With a market capitalization of $264.17M, it holds a significant position in the sector. When comparing efficiency, DMAA's gross margin of N/A stands against OACC's N/A and CATL's N/A. Such benchmarking helps identify whether Drugs Made In America Acquisition Corp. is trading at a premium or discount relative to its financial performance.

The net income for Q2 2026 was $1,726,897, down from $2,284,579 in Q2 2025, indicating a decline in profitability. The EPS for Q2 2026 is $0.06, which is lower than the previous quarters, reflecting inconsistent earnings performance.